September 15, 2014

Clinical trials results suggest medicines could slow IPF progression

LFA-IPFR-logo_CMYK

Lung Foundation Australia and the Australian IPF Registry Steering Committee welcomed the findings of two major studies released at the American Thoracic Society 2014 Congress in San Diego in April, which showed IPF could be successfully treated with new medicines that slow disease progression.

The results of the INPULSIS and ASCEND trials were not only of academic interest but also have considerable implications for the care of IPF patients. Australia played a key role in recruiting patients to both the INPULSIS and ASCEND studies.

The two new therapies studied in these clinical trials, nintedanib and pirfendione may become available in Australia in the coming months. If approved, these exciting results are likely to change the management of Australian IPF patients.

For further information on these medications, patients are advised to contact their respiratory physician.

Health professionals can contact the Registry Coordinator in their state to inform them of their IPF patients who are interested in joining the Registry.  To find the Coordinator in their state please call Sacha Macansh on 02 9515 3996, email ipf@lungfoundation.com.au and visit our website here.

The Australian IPF Registry Steering Committee is keen to ensure Respiratory physicians and their health care teams are kept up-to-date with latest information and concepts. They encouraged health care professionals to join the Registry special interest group AUS IPF-net. Members are kept informed by e-newsletters about IPF research findings, clinical trials and Registry progress.

If you are a health care professional and not already a member of AUS IPF-net please join by emailing ipf@lungfoundation.com.au or calling the Australian IPF Registry Project Manager Sacha Macansh on 02 9515 3996.